Journal of psychiatric research · 2025
Comparison of premenstrual dysphoric disorder treatment with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Berni Luigi Chermont, Nunes Leticia Ribeiro, Oliveira Rita de Cássia Silva de
Аннотация
OBJECTIVE: Evaluate the treatment of Premenstrual Dysphoric Disorder (PMDD) with antidepressants and combined oral contraceptives (COCs) in order to identify the most appropriate treatments available, with the best tolerability and acceptability.
RESULTS: Sixteen studies were included in the systematic review, of which five were incorporated into the network meta-analysis. Continuous paroxetine showed the greatest effect across all evaluated symptom domains. The 24/4 DROS/EE regimen was the most effective COC, showing particularly positive outcomes for both physical and emotional symptoms.
CONCLUSIONS: The network meta-analysis indicates that both SSRIs and COCs are effective in managing PMDD, with continuous paroxetine and DROS/EE 24/4 emerging as the most effective strategies in their respective categories. Treatment choice should consider predominant symptom patterns, individual tolerability, and reproductive planning. Further direct comparative clinical trials between these therapeutic classes are needed to guide clinical decision-making with greater precision.
RESULTS: Sixteen studies were included in the systematic review, of which five were incorporated into the network meta-analysis. Continuous paroxetine showed the greatest effect across all evaluated symptom domains. The 24/4 DROS/EE regimen was the most effective COC, showing particularly positive outcomes for both physical and emotional symptoms.
CONCLUSIONS: The network meta-analysis indicates that both SSRIs and COCs are effective in managing PMDD, with continuous paroxetine and DROS/EE 24/4 emerging as the most effective strategies in their respective categories. Treatment choice should consider predominant symptom patterns, individual tolerability, and reproductive planning. Further direct comparative clinical trials between these therapeutic classes are needed to guide clinical decision-making with greater precision.